Abstract
We summarize here in vitro evidences of efficacy for convalescent plasma, currently approved vaccines and monoclonal antibodies against SARS-CoV-2 variants of concern (VOC: B.1.1.7, B.1.351, P.1, and B.1.617.2), variants of interest (VOI: B.1.427/B.1.429, P.2, B.1.525, P.3, B.1.526, and B.1.671.1), and other strains (B.1.1.298 and B.1.258delta). While waiting from real world clinical efficacy, these data provide guidance for the treating physician.
Subject
Virology,Infectious Diseases
Reference100 articles.
1. COVID-19 Weekly Epidemiological Update 25 February 2021. Special Edition: Proposed Working Definitions of SARS-CoV-2 Variants of Interest and Variants of Concernhttps://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update
2. Viral infection neutralization tests: A focus on SARS-CoV-2 with implications for convalescent plasma therapy;Focosi;Rev. Med. Virol.,2020
3. Emergence of SARS-CoV-2 Spike Escape Mutation Q493R After Bamlanivimab/Etesevimab Treatment for COVID-19
4. Revealing the threat of emerging SARS-CoV-2 mutations to antibody therapies
5. Comprehensive mapping of neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination
Cited by
30 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献